HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Says Supplement AERs Will Be Subject To Lower Threshold Before Action

This article was originally published in The Tan Sheet

Executive Summary

FDA will continue to take actions against dietary supplement products prompted by a lower tolerance for adverse events than for other types of products, a policy reflected in its request for a recall the Hydroxycut weight-loss product line

You may also be interested in...

Supplement AERs Require Less Forgiving Risk/Benefit Calculation - FDA

FDA applies a lower tolerance for risk in evaluating serious adverse event reports for dietary supplements than for drug AERs because of the "uncertainty" surrounding supplement products, an agency official says

Novartis' Maalox Total Relief Rebranding Reflects FDA AER Evolution

FDA's request that Novartis rebrand a Maalox line extension is the latest illustration of the agency taking action based on a relatively small number of serious adverse event reports

FDA Suggests Supplement Firms Use MedDRA Internally For AER Data

FDA suggests supplement firms keep internal records of adverse event data with the same coding system for medical conditions and symptoms that the agency uses

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts